Trump slaps 30% tariffs on EU, Mexico
On Monday, RBC analysts highlighted potential risks for Galderma stock due to newly imposed 25% tariffs on imports from Canada by the United States.
Galderma, which has previously outlined its vulnerability to global tariffs, acknowledged that its injectable aesthetics business, produced mainly in the UK and EU, contributes the most economic value imported into the US.
The company specifically pointed to Cetaphil, a product within its Dermatological Skincare segment, as being manufactured in Canada for the US market, representing less than 10% of the group's sales.
The tariffs will affect only the transfer price component of these imports, the exact figures for which Galderma has not disclosed. As the company navigates the implications of the tariff changes announced over the weekend, it is working to assess the potential impact on its operations and financials.
Galderma has committed to providing updates during the disclosure of its 2025 guidance at the fiscal year results on March 6th.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.